Delving into the Latest Updates on Medesis Pharma SA with Synapse

Overview

Tags

Nervous System Diseases

Congenital Disorders

Neoplasms

siRNA

Small molecule drug

Oncolytic virus

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	3
Neoplasms	2
Endocrinology and Metabolic Disease	1
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	2
siRNA	2
Synthetic peptide	1
Oncolytic virus	1

Top 5 Target	Count

IFNAR(Interferon alpha/beta receptor)	1
IFNAR-1(Interferon-alpha/beta receptor alpha chain)	1
BACE1 x GSK-3β	1

This is a prospective, multicenter, randomized (3:1), placebo- controlled, parallel-group, double-blind trial.
Patients will be randomized into two arms of treatment:
Placebo + SoC (N=30)
NanoManganese® + SoC (N=90)
Patients will be treated and followed-up for 10 days:
Arterial oxygen partial pressure (PaO2) will be measured at baseline and at days 3, 5 and 10,
Oxygen saturation, vital signs including respiration rate, pulse rate, blood pressure and body temperature, disease severity (7-point ordinal scale and NEWS2 score) will be measured at baseline and daily,
Hematology and biochemistry measurements will be done at baseline and at day 3, 5 and 10,
Pharmacokinetic (Blood Mn concentration) measurements will be done at baseline and at day 3, 5 and 10,
Biomarkers will be measured at baseline and at day 3, 5 and 10. At the end of the 10-day treatment period, a follow-up visit will be planned between day 15 and day 22. The following.
assessments/examinations will be performed: oxygen saturation, vital signs including respiration rate and body temperature, disease severity (7-point ordinal scale and NEWS2 score), electrocardiogram (ECG), hematology, biochemistry, concomitant therapies, and adverse events.

Start Date04 Feb 2022

Sponsor / Collaborator

Medesis Pharma SA

EUCTR2021-001273-23-FR / Unknown statusPhase 2

A prospective, multicenter, with a first part randomized, placebo-controlled, parallel-group, double-blind period followed by an open-label trial period trial to evaluate the clinical safety and efficacy of NanoLithium® NP03 in patients with moderate-to-severe Alzheimer’s disease: a proof-of-concept study - NanoLi®_AD

Start Date20 Sep 2021

Sponsor / Collaborator

Medesis Pharma SA

100 Clinical Results associated with Medesis Pharma SA

Login to view more data

0 Patents (Medical) associated with Medesis Pharma SA

Login to view more data

11

Literatures (Medical) associated with Medesis Pharma SA

01 Mar 2021·NeuropharmacologyQ2 · MEDICINE

Exposure of R6/2 mice in an enriched environment augments P42 therapy efficacy on Huntington's disease progression

Q2 · MEDICINE

Article

Author: Carles, Allison ; Maschat, Florence ; Benigno-Anton, Lorraine ; Denus, Morgane ; Couly, Simon ; Maurice, Tangui

Huntington's disease (HD) is due to a mutation in the gene encoding for Huntingtin protein generating polyQ domain extension. Mutant Htt (mHtt) leads to important dysfunction of the BDNF/TrkB signaling. We previously described the 23aa Htt fragment P42, that attenuated the pathological phenotypes induced by mHtt. We reported that, in the R6/2 mouse model of HD, P42 rescued striatal TrkB level but marginally increased cortical BDNF. In the present study, our aim was to address P42 neuroprotection in presence of an external input of BDNF. We combined P42 administration with environmental enrichment (EE), induced by training in the Hamlet test. We examined the consequences of P42 + EE combination on different phenotypes in R6/2 HD mice: motor and cognitive performances, recorded at early and late pathological stages, and analyzed aggregated mHtt and BDNF levels in forebrain structures. Hamlet exploration (i.e., entries in Run, Hide, Eat, Drink and Interact houses) was gradually impaired in R6/2 mice, but maintained by P42 treatment until week 8. Topographic memory alteration measured at week 7 was attenuated by P42. Motor performances (rotarod) were significantly ameliorated by the P42 + EE combination until late stage (week 12). The P42 + EE combination also significantly decreased aggregated Htt levels in the hippocampus, striatum and cortex, and increased BDNF levels in the cortex and striatum. We concluded that combination between P42 treatment, known to increase TrkB striatal expression, and a BDNF-enhancing therapy such as EE efficiently delayed HD pathology in R6/2 mice. Use of dual therapies might be a pertinent strategy to fight neurodegeneration in HD.

01 Sep 2018·Human Molecular Genetics

Improvement of BDNF signalling by P42 peptide in Huntington's disease

Article

Author: Maschat, Florence ; Jourdan, Christophe ; Paucard, Alexia ; Bonneaud, Nathalie ; Maurice, Tangui ; Vignes, Michel ; Cohen-Solal, Catherine ; Couly, Simon ; Benigno, Lorraine

Huntington's disease (HD) is caused by a mutation in the Huntingtin (HTT) protein. We previously reported that the 23aa peptide of HTT protein, P42, is preventing HD pathological phenotypes, such as aggregation, reduction of motor performances and neurodegeneration. A systemic treatment with P42 during the pre-symptomatic phase of the disease showed therapeutic potential in R6/2 mice. We here tested P42 effects when administered during the post-symptomatic phase. The P42 treatment alleviated deficits in motor performances, even when symptoms have already started. Because changes in the level and activity of brain-derived neurotrophic factor (BDNF) have been shown to play a central role in HD, we analysed the influence of P42 on BDNF deficit and associated phenotypes. Our data suggest that P42 is involved in the spatio-temporal control of bdnf and trkB mRNA and their protein levels. Related to this enhancement of BDNF-TrkB signalling, R6/2 mice treated with P42, exhibit reduced anxiety, better learning and memory performances, and better long-term potentiation (LTP) response. Finally we identified a direct influence of P42 peptide on neuronal plasticity and activity. These results suggest that P42 offers an efficient therapeutic potential not only by preventing aggregation of mutant HTT at early stages of the disease, but also by favouring some physiological functions of normal HTT, as P42 is naturally part of it, at the different stages of the disease. This makes P42 peptide potentially suitable not only to prevent, but also to treat HD.

01 Apr 2016·International Journal of PharmaceuticsQ2 · MEDICINE

Formulation, physicochemical characterization and stability study of lithium-loaded microemulsion system

Q2 · MEDICINE

Article

Author: Mouri, Abdelkader ; Dorandeu, Christophe ; Maurel, Jean Claude ; Devoisselle, Jean-Marie ; Legrand, Philippe ; El Ghzaoui, Abdeslam

Lithium biocompatible microemulsion based on Peceol(®), lecithin, ethanol and water was studied in attempt to identify the optimal compositions in term of drug content, physicochemical properties and stability. Lithium solubilization in microemulsion was found to be compatible with a drug-surfactant binding model. Lithium ions were predominantly solubilized within lecithin head group altering significantly the interfacial properties of the system. Pseudo-ternary phase diagrams of drug free and drug loaded microemulsions were built at constant ethanol/lecithin weight ratio (40/60). Lithium loaded microemulsion has totally disappeared in the Peceol(®) rich part of phase diagram; critical fractions of lecithin and ethanol were required for the formation of stable microemulsion. The effect of lithium concentration on the properties and physical stability of microemulsions were studied using microscopy, Karl Fischer titrations, rheology analyses, conductivity measurements and centrifugation tests. The investigated microemulsions were found to be stable under accelerated storage conditions. The systems exhibited low viscosity and behaved as Newtonian fluid and no structural transition was shown.

100 Deals associated with Medesis Pharma SA

Login to view more data

100 Translational Medicine associated with Medesis Pharma SA

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

3

Preclinical

Phase 1 Clinical

1

Phase 2 Clinical

Other

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Lithium Citrate ( BACE1 x GSK-3β )	Alzheimer Disease More	Phase 2
NP-01(Medesis Pharma SA)	Diabetes Mellitus, Type 2 More	Phase 1
NanosiRNA HD	Huntington Disease More	Preclinical
NanoP42T HD	Huntington Disease More	Preclinical
NanosiRNA IFNAR ( IFNAR )	Neoplasms More	Preclinical